Lead author/reference | Chemotherapy regimen | Admissions interval (median courses) | Number of patients | Response rate | Median survival (months) |
---|---|---|---|---|---|
Vogelzang [14] | Cisplatin (75mg/m2 on day one)/pemetrexed (500mg/m2 on day one) | Every three weeks, 6.0 courses | 226 | 41 percent | 12.1 |
Nakano [15] | Cisplatin (60mg/m2 on day one)/irinotecan (60mg/m2 on days one, eight, and 15) | Every four weeks, 2.6 courses | 15 | 27 percent | 6.5 |
Tsavaris [16] | Cisplatin (100mg/m2 on day one)/vinblastine (6mg/m2 on days one and eight) | Every four weeks, 4.0 courses | 20 | 25 percent | N/A |
Ardizzoni [17] | Cisplatin (60mg/m2 on day 1)/doxorubicin (60mg/m2 on day one) | Every three to four weeks, 3.0 to 4.0 courses | 26 | 25 percent | 10 |
Nowak [18] | Cisplatin (100mg/m2 on day one)/gemcitabine (1000mg/m2 on days one, eight, and 15) | Every four weeks, 4.0 courses | 53 | 33 percent | 11.2 |
Present report | Cisplatin (60mg/m2 on day one)/irinotecan (60mg/m2 on days one, eight, and 15) | One course with hyperthermia | Â | Complete response | >84 |